A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
Miso Kim, Jeong‐Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong‐Wan Kim, Jong Seok Lee, Dae Seog Heo
Abstract
Not available.
Topics & Concepts
Brentuximab vedotinCD30Refractory (planetary science)MedicineInternal medicineOncologyEpstein–Barr virusVirologyVirusLymphomaBiologyAstrobiologyLymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders researchViral-associated cancers and disorders